SUBSCRIBE
SUBSCRIBE
News   Drug Development

Analyst: Roche May Drop Taspoglutide Diabetes Drug

June 28, 2010 | 
1 min read
IndyStar -- Roche Holding AG may drop development of the taspoglutide diabetes drug and return the rights to developer Ipsen SA because the treatment has too many side effects, Morgan Stanley analysts said.
Clinical research Phase 2
Roche
MORE ON THIS TOPIC
Fashionable halftone collage. Concept of partnership, sponsorship,agreement, contract conclusion. Illustration for web banner, social media banner, business presentation, marketing material. Vector illustration
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
May 18, 2026
 · 
2 min read
 · 
Gabrielle Masson
Human liver organ and pills. World hepatitis day. National liver health awareness month. Liver transplantation, donation background. Save patient life in hospital with liver transplant
Postmarket research
Amgen’s rare disease drug Tavneos tied to 20 deaths in Japan
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Cancer
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac
Sorting garbage concept. Cropped photo of paper thash. Crumple paper falling to the recycling bin
Drug Development
Genmab drops 2 antibody assets, including another ProfoundBio ADC
May 15, 2026
 · 
2 min read
 · 
Gabrielle Masson